NCT06119685RecruitingPhase 1/2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Source: ClinicalTrials.gov · Last updated 3 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- First submitted
- 22 Oct 2023
- Start date
- 25 Oct 2023
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- Indapta Therapeutics, INC.
- Diseases
- Multiple myeloma
- NCT number
- NCT06119685
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 128
- From 25 Oct 2023 to the primary completion date, 30 Dec 2025
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Impaired cardiac function or history of clinical significant cardiac disease.
- Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
- Active SARS-CoV-2 infection.
Other
- Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.
Who the study is looking for
- For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after ≥ 3 prior lines of therapy.
- For NHL patients: R/R disease and failed ≥ 2 lines of systemic chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of greater than 12 weeks per the Investigator.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory University Hospital Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
| University Hospitals Cleveland Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
| NEXT Oncology- Virginia Coordinator of this site? Confirm its status | Fairfax | United States | Recruiting |
| University of Texas - MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center Coordinator of this site? Confirm its status | Lake Mary | United States | Withdrawn |
| Valkyrie Clinical Trials Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
| University of Minnesota Coordinator of this site? Confirm its status | Minneapolis | United States | Recruiting |
| SCRI Oncology Partners Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
| NYP/Weill Cornell Medical Center Coordinator of this site? Confirm its status | New York | United States | Withdrawn |
| Providence Cancer Institute Franz Clinic Coordinator of this site? Confirm its status | Portland | United States | Withdrawn |
| Rhode Island Hospital Coordinator of this site? Confirm its status | Providence | United States | Recruiting |
| Atrium Health Wake Forest Baptist Coordinator of this site? Confirm its status | Winston-Salem | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.